A case of antibody formation against octreotide visualized with 111In-octreotide scintigraphy.
A case of antibody formation in a patient with carcinoid syndrome is described. The patient was treated with octreotide in dosages up to 1.5 mg/day. Serum samples were analysed for the presence of octreotide antibodies before and after 20 months of octreotide treatment. In-vivo 111In-octreotide scintigraphy was performed before and during therapy, and after antibodies had developed. Before treatment, no serum antibodies against octreotide were detected. After 20 months of treatment, they were detectable up to a 1:115 serum dilution. The serum binding of 125I-Tyr3-octreotide was blocked by adding excess unlabelled Tyr3-octreotide, indicating the presence of specific octreotide antibodies. Before treatment, a normal distribution of radioactivity in the spleen and kidneys, irregular uptake in the liver due to metastases, and a hot spot in the lower abdomen were found during 111In-octreotide scintigraphy. After antibodies had developed, increased radioactivity over the heart and high background radioactivity in the abdomen with only faint visualization of the spleen, liver, and kidneys were found, indicating a prolonged presence of 111In-octreotide in the blood resulting from its being bound to antibodies. Increased radioactivity was also seen at the injection sites of the drug in the upper legs. In-vitro incubation of biopsy tissue from this site with 125I-Tyr3-octreotide revealed diffuse guanosine triphosphate (GTP) independent specific binding, indicating non-G-protein linked binding of labelled octreotide. This report describes the characteristic abnormalities during in-vivo 111In-octreotide scintigraphy in a patient with octreotide antibodies.(ABSTRACT TRUNCATED AT 250 WORDS)
Kwekkeboom
D J
DJ
Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Assies
J
J
Hofland
L J
LJ
Reubi
J C
JC
Lamberts
S W
SW
Krenning
E P
EP
D000368:Aged; D000906:Antibodies / Q000276:immunology*; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D007668:Kidney / Q000000981:diagnostic imaging; D008099:Liver / Q000000981:diagnostic imaging; D015282:Octreotide / Q000276:immunology* / Q000627:therapeutic use; D011877:Radionuclide Imaging; D012867:Skin / Q000000981:diagnostic imaging; D013154:Spleen / Q000000981:diagnostic imaging
D000906:Antibodies; D007205:Indium Radioisotopes; D015282:Octreotide